Corcept Therapeutics IncNASDAQ:CORT
- LAST PRICE52.4068
- TODAY'S CHANGE (%)-2.3832 (-4.3497%)
- Bid / Lots52.3600/ 7
- Ask / Lots52.4600/ 3
- Open / Previous Close55.0900 / 54.7900
- Day Range
- 52 Week Range
- Volume517,964
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CORT |
|---|---|---|
| 09:32 ET | 22518 | 54.715 |
| 09:33 ET | 851 | 54.915 |
| 09:35 ET | 435 | 55.04 |
| 09:37 ET | 300 | 54.975 |
| 09:39 ET | 400 | 54.97 |
| 09:42 ET | 1300 | 54.58 |
| 09:44 ET | 422 | 54.405 |
| 09:46 ET | 6608 | 54.32 |
| 09:48 ET | 4008 | 54.5663 |
| 09:50 ET | 3723 | 54.365 |
| 09:51 ET | 4682 | 54.385 |
| 09:53 ET | 18850 | 54.07 |
| 09:55 ET | 2704 | 54.065 |
| 09:57 ET | 900 | 54 |
| 10:00 ET | 900 | 54.065 |
| 10:02 ET | 800 | 54.205 |
| 10:04 ET | 5754 | 54.05 |
| 10:06 ET | 8157 | 54.03 |
| 10:08 ET | 5218 | 54.05 |
| 10:09 ET | 2961 | 54.025 |
| 10:11 ET | 8169 | 53.5 |
| 10:13 ET | 3407 | 53.56 |
| 10:15 ET | 3803 | 53.71 |
| 10:18 ET | 1407 | 53.6 |
| 10:20 ET | 2400 | 53.36 |
| 10:22 ET | 4320 | 53.3142 |
| 10:24 ET | 4300 | 53.54 |
| 10:26 ET | 400 | 53.35 |
| 10:27 ET | 400 | 53.31 |
| 10:29 ET | 1300 | 53.45 |
| 10:31 ET | 2334 | 53.16 |
| 10:33 ET | 1172 | 53.29 |
| 10:36 ET | 3903 | 53.14 |
| 10:38 ET | 1925 | 53.0701 |
| 10:40 ET | 1402 | 53.245 |
| 10:42 ET | 1650 | 53.14 |
| 10:44 ET | 2175 | 53.1 |
| 10:45 ET | 3652 | 53.18 |
| 10:47 ET | 200 | 53.2 |
| 10:49 ET | 500 | 53.28 |
| 10:51 ET | 1082 | 53.54 |
| 10:54 ET | 2779 | 53.4 |
| 10:56 ET | 906 | 53.4 |
| 10:58 ET | 2028 | 53.285 |
| 11:00 ET | 2153 | 53.31 |
| 11:02 ET | 1600 | 52.98 |
| 11:03 ET | 2699 | 53.11 |
| 11:05 ET | 714 | 53.1078 |
| 11:07 ET | 3512 | 53.05 |
| 11:09 ET | 4311 | 53.09 |
| 11:12 ET | 5239 | 53.03 |
| 11:14 ET | 4052 | 53.23 |
| 11:16 ET | 2340 | 53.19 |
| 11:18 ET | 1181 | 53.14 |
| 11:20 ET | 3124 | 53.15 |
| 11:21 ET | 400 | 53.09 |
| 11:23 ET | 19091 | 53.13 |
| 11:25 ET | 1951 | 53.13 |
| 11:27 ET | 2212 | 53.08 |
| 11:30 ET | 2900 | 53.04 |
| 11:32 ET | 1177 | 53.04 |
| 11:34 ET | 1530 | 53.03 |
| 11:38 ET | 1900 | 52.96 |
| 11:39 ET | 701 | 53 |
| 11:41 ET | 1800 | 52.95 |
| 11:43 ET | 1655 | 52.86 |
| 11:45 ET | 1450 | 52.865 |
| 11:48 ET | 4650 | 52.74 |
| 11:50 ET | 9106 | 52.54 |
| 11:52 ET | 15176 | 52.6665 |
| 11:54 ET | 4881 | 52.655 |
| 11:56 ET | 6074 | 52.645 |
| 11:57 ET | 6160 | 52.66 |
| 11:59 ET | 5526 | 52.725 |
| 12:01 ET | 1878 | 52.81 |
| 12:03 ET | 3760 | 52.6213 |
| 12:06 ET | 700 | 52.6 |
| 12:08 ET | 4743 | 53 |
| 12:10 ET | 1200 | 53.035 |
| 12:12 ET | 1410 | 52.93 |
| 12:14 ET | 400 | 52.87 |
| 12:15 ET | 600 | 52.91 |
| 12:17 ET | 300 | 52.94 |
| 12:19 ET | 2064 | 52.88 |
| 12:21 ET | 512 | 52.84 |
| 12:24 ET | 100 | 52.84 |
| 12:26 ET | 640 | 52.8518 |
| 12:28 ET | 200 | 52.89 |
| 12:30 ET | 1666 | 52.79 |
| 12:32 ET | 300 | 52.81 |
| 12:33 ET | 1223 | 52.79 |
| 12:35 ET | 2165 | 52.7 |
| 12:37 ET | 1571 | 52.69 |
| 12:39 ET | 500 | 52.76 |
| 12:42 ET | 702 | 52.74 |
| 12:44 ET | 18500 | 52.71 |
| 12:46 ET | 1283 | 52.86 |
| 12:48 ET | 300 | 52.805 |
| 12:50 ET | 1813 | 53.04 |
| 12:51 ET | 500 | 53.045 |
| 12:53 ET | 3832 | 52.95 |
| 12:55 ET | 600 | 52.72 |
| 12:57 ET | 100 | 52.785 |
| 01:00 ET | 100 | 52.795 |
| 01:02 ET | 350 | 52.858 |
| 01:04 ET | 100 | 52.8555 |
| 01:06 ET | 1600 | 52.61 |
| 01:08 ET | 900 | 52.61 |
| 01:13 ET | 1800 | 52.52 |
| 01:15 ET | 1400 | 52.6 |
| 01:18 ET | 923 | 52.57 |
| 01:20 ET | 1700 | 52.64 |
| 01:22 ET | 300 | 52.61 |
| 01:24 ET | 200 | 52.65 |
| 01:26 ET | 2180 | 52.54 |
| 01:27 ET | 1462 | 52.52 |
| 01:29 ET | 744 | 52.535 |
| 01:33 ET | 907 | 52.54 |
| 01:36 ET | 2138 | 52.52 |
| 01:38 ET | 7315 | 52.46 |
| 01:40 ET | 4169 | 52.5 |
| 01:42 ET | 3568 | 52.46 |
| 01:44 ET | 6469 | 52.4068 |
Oct 31, 2024
DJ Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:28AM ET on Thursday Oct 31, 2024 by Dow Jones
7:28AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones*DJ Corcept Therapeutics 3Q EPS 41c >CORT, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 23, 2024
Press Release: Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call, from 5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones
5:11PM ET on Wednesday Oct 23, 2024 by Dow JonesPress Release: Correction: Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call, from 5:05PM ET on Wednesday Oct 23, 2024 by Dow Jones
5:05PM ET on Wednesday Oct 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Corcept Therapeutics Inc | 5.7B | 41.3x | +9.80% |
Harmony Biosciences Holdings Inc | 1.9B | 15.7x | --- |
Amphastar Pharmaceuticals Inc | 2.2B | 15.0x | --- |
ANI Pharmaceuticals Inc | 1.2B | -127.7x | -8.16% |
Roivant Sciences Ltd | 8.5B | 2.0x | --- |
HUTCHMED (China) Ltd | 2.9B | -66.8x | --- |
Company Information
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Contact Information
- Headquarters
- 101 REDWOOD SHORES PARKWAYREDWOOD CITY, CA, United States 94065
- Phone
- 650-688-8803
- Fax
- 650-327-3218
Executives
- Independent Chairman of the Board
- James Wilson
- President, Chief Executive Officer, Co-Founder, Director
- Joseph Belanoff
- Chief Financial Officer, Treasurer
- Atabak Mokari
- President - Corcept Endocrinology
- Sean Maduck
- President - Oncology
- Roberto Vieira
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.7B |
|---|---|
Revenue (TTM) | $628.6M |
Shares Outstanding | 104.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $1.27 |
Book Value | $4.90 |
P/E Ratio | 41.3x |
Price/Sales (TTM) | 9.1 |
Price/Cash Flow (TTM) | 40.2x |
Operating Margin | 22.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
